Neonatal hypoxia-ischemia: cellular and molecular brain damage and therapeutic modulation of neurogenesis
INTRODUCTION:
Perinatal asphyxia remains a major cause of both mortality
and neurological morbidity. Neonatal encephalopathy affects to 1-3/1,000
newborns, leading to significant brain damage and childhood disability. The
only standard therapy is moderate hypothermia, whose efficacy, despite proved,
is limited, being partially effective.
DEVELOPMENT:
The capacity of hypothermia in promoting cell proliferation
in the neurogenic niches of the central nervous system remains subject of
investigation. The use of therapeutic agents such as erythropoietin and
cannabinoids and mesenchymal stem cells have shown promising results in
experimental models of perinatal asphyxia, being able of modulate neurogenesis,
neuronal plasticity and neuroreparation processes after hypoxic-ischemic brain
injury.
CONCLUSIONS:
The effects of these therapies in clinics are still unknown,
so as if the newborn cells will be able to effectively integrate in the
existing neuronal networks or if they will develop their proper functions in a
brain-damaged microenvironment, thus being necessary new works focused on the
evaluation of the real potential of these therapies in the modulation of
neurogenesis after neonatal hypoxia-ischemia.
